CG icon

Carlyle Group

42.36 USD
+1.86
4.59%
At close Mar 14, 4:00 PM EDT
After hours
41.50
-0.86
2.03%
1 day
4.59%
5 days
0.83%
1 month
-18.18%
3 months
-19.71%
6 months
3.12%
Year to date
-16.50%
1 year
-6.18%
5 years
127.50%
10 years
61.37%
 

About: The Carlyle Group is one of the world's largest alternative-asset managers, with $447.4 billion in total AUM, including $313.6 billion in fee-earning AUM, at the end of September 2024. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure, and natural resources funds (accounting for 33% of fee-earning AUM and 57% of base management fees during 2023), global credit (51% and 27%) and investment solutions (16% and 16%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving more than 2,900 active carry fund investors from 88 countries.

Employees: 2,300

0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

206% more call options, than puts

Call options by funds: $149M | Put options by funds: $48.9M

114% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 43

67% more funds holding in top 10

Funds holding in top 10: 6 [Q3] → 10 (+4) [Q4]

21% more capital invested

Capital invested by funds: $9.01B [Q3] → $10.9B (+$1.87B) [Q4]

7% more funds holding

Funds holding: 516 [Q3] → 553 (+37) [Q4]

1.57% more ownership

Funds ownership: 58.67% [Q3] → 60.23% (+1.57%) [Q4]

1% more repeat investments, than reductions

Existing positions increased: 186 | Existing positions reduced: 185

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$52
23%
upside
Avg. target
$54
27%
upside
High target
$55
30%
upside

3 analyst ratings

positive
33%
neutral
67%
negative
0%
Wells Fargo
Michael Brown
42% 1-year accuracy
25 / 60 met price target
27%upside
$54
Equal-Weight
Maintained
12 Feb 2025
Evercore ISI Group
Glenn Schorr
54% 1-year accuracy
19 / 35 met price target
23%upside
$52
In-Line
Maintained
12 Feb 2025
Barclays
Benjamin Budish
63% 1-year accuracy
78 / 124 met price target
30%upside
$55
Overweight
Maintained
12 Feb 2025

Financial journalist opinion

Based on 25 articles about CG published over the past 30 days

Neutral
Bloomberg Markets and Finance
1 day ago
Carlyle's Currie on Canada Tariffs, Energy Security, Oil, Aluminum and Copper Prices
Jeff Currie, Carlyle Chief Strategy Officer of Energy Pathways, talks about the oil market outlook, the need for energy security and the US increasing tariffs on steel and aluminum from Canada. He speaks to Bloomberg's Alix Steel at CERAWeek in Houston.
Carlyle's Currie on Canada Tariffs, Energy Security, Oil, Aluminum and Copper Prices
Neutral
Accesswire
1 day ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
NEW YORK, NY / ACCESS Newswire / March 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Neutral
Accesswire
2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Neutral
Accesswire
3 days ago
bluebird bio Investor Alert: Is the Proposed Acquisition of bluebird bio Fair to bluebird bio Investors - Kehoe Law Firm, P.C. Investigating - BLUE
PHILADELPHIA, PA / ACCESS Newswire / March 12, 2025 / Kehoe Law Firm, P.C. continues its investigation on behalf of investors of bluebird bio (NASDAQ:BLUE) regarding the adequacy and fairness of the proposed acquisition of bluebird bio by "funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP ("SK Capital") in collaboration with a team of highly experienced biotech executives.
bluebird bio Investor Alert: Is the Proposed Acquisition of bluebird bio Fair to bluebird bio Investors - Kehoe Law Firm, P.C. Investigating - BLUE
Neutral
PRNewsWire
4 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
NEW YORK , March 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ: BLUE).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Neutral
Accesswire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
NEW YORK, NY / ACCESS Newswire / March 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Neutral
Accesswire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Neutral
Accesswire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Negative
Bloomberg Markets and Finance
1 week ago
Carlyle CEO Says ‘Buckle Up' as Trump Tariffs Take Hold
Carlyle Group CEO Harvey Schwartz told investors to “buckle up a bit” for more market volatility as Trump Administration tariffs kick in. Schwartz spoke Tuesday at the Bloomberg Invest conference in New York.
Carlyle CEO Says ‘Buckle Up' as Trump Tariffs Take Hold
Neutral
PRNewsWire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
NEW YORK , March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ: BLUE).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Charts implemented using Lightweight Charts™